Ultime prove

EudraCT Number: 2022-000648-32

Sponsor Protocol Number: SCY-078-302

Start Date: 2023-03-31

Sponsor Name: SCYNEXIS, Inc.

Full Title: A Phase 3, Multicenter, Prospective, Randomized, Double-blind Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin followed by Oral Ibrexafungerp ver...

Medical condition: Invasive Candidiasis/ Candidemia

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000004862	10060573	Candidemia	LLT
	20.0	100000004862	10064954	Invasive candidiasis	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GR (Ongoing) ES (Temporarily Halted) BG (Ongoing) IT (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-003365-38

Sponsor Protocol Number: VTX958-202

Start Date: 2023-03-31

Sponsor Name: Ventyx Biosciences, Inc.

Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Participants with Moderately to Severely Active Crohn’s D...

Medical condition: Moderately to severely active Crohn’s disease

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10017947 - Gastrointestinal disorders	10011401	Crohn's disease	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: SK (Ongoing) LT (Ongoing) DE (Ongoing) HU (Ongoing) IT (Ongoing) PL (Ongoing) BG (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-002757-26

Sponsor Protocol Number: BH-200-03

Start Date: 2023-03-28

Sponsor Name: HMNC Holding GmbH

Full Title: A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) i...

Medical condition: Major Depressive Disorder

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10037175 - Psychiatric disorders	10057840	Major depression	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: LT (Ongoing) BG (Ongoing) DE (Ongoing) ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-003124-41

Sponsor Protocol Number: 219510

Start Date: 2023-03-27

Sponsor Name: GlaxoSmithKline Biologicals SA

Full Title: A non-randomized, open label, multi-country, cohort study to describe the safety of study participants who received RSVPreF3 maternal vaccination (any dose) or controls from previous RSV MAT studie...

Medical condition: Pregnancy related outcomes and events in maternal participants who were vaccinated against RSV or received control, and in their infants

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10036585 - Pregnancy, puerperium and perinatal conditions	10070538	Gestational hypertension	PT
	20.0	10036585 - Pregnancy, puerperium and perinatal conditions	10036485	Pre-eclampsia	PT
	25.0	10036585 - Pregnancy, puerperium and perinatal conditions	10086971	Pre-eclampsia with severe features	LLT
	20.0	10036585 - Pregnancy, puerperium and perinatal conditions	10070532	Fetal growth restriction	LLT
20.0	10036585 - Pregnancy, puerperium and perinatal conditions	10073024	Preterm premature rupture of membranes	PT
21.1	10036585 - Pregnancy, puerperium and perinatal conditions	10075863	Preterm labor	LLT
21.1	10036585 - Pregnancy, puerperium and perinatal conditions	10018210	Gestational diabetes mellitus	LLT
20.0	100000004862	10008755	Chorioamnionitis	LLT
21.1	10036585 - Pregnancy, puerperium and perinatal conditions	10041093	Small for gestational age	LLT
21.1	10036585 - Pregnancy, puerperium and perinatal conditions	10067508	Low birth weight baby	PT
21.1	10036585 - Pregnancy, puerperium and perinatal conditions	10067509	Very low birth weight baby	LLT
21.1	10036585 - Pregnancy, puerperium and perinatal conditions	10074164	Extremely low birth weight baby	LLT
20.1	10018065 - General disorders and administration site conditions	10011912	Death neonatal	PT
25.0	10042613 - Surgical and medical procedures	10086969	Medically induced preterm birth	PT

Population Age: Children, Adolescents, Under 18, Adults

Gender: Female

Trial protocol: FI (Ongoing) BE (Ongoing) FR (Ongoing) ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-002389-33

Sponsor Protocol Number: CNTO1959CRD3007

Start Date: 2023-03-27

Sponsor Name: Janssen-Cilag International NV

Full Title: A Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Guselkumab for the Treatment of Participants with Crohn’s Disease After Surgical Resection

Medical condition: Crohn’s Disease After Surgical Resection

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10017947 - Gastrointestinal disorders	10011401	Crohn's disease	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Temporarily Halted) HU (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-002792-11

Sponsor Protocol Number: KAN0007

Start Date: 2023-03-27

Sponsor Name: Kancera AB

Full Title: KANDOVA - A two-part Phase Ib/IIa study to evaluate the safety and tolerability of KAND567, in combination with carboplatin therapy, and to determine the Recommended Phase II Dose (RPIID) of KAND56...

Medical condition: Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10033128	Ovarian cancer	PT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: NO (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-003628-42

Sponsor Protocol Number: NBK182/1/2022

Start Date: 2023-03-24

Sponsor Name: Medical University of Gdańsk

Full Title: A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Levosimendan Therapy in low ejection fraction Takotsubo Syndrome (LevoTako Trial)

Medical condition: Takotsubo syndrome (TTS), also known as apical ballooning syndrome, Takotsubo cardiomyopathy, broken heart syndrome, and stress-induced cardiomyopathy, is a rare condition and accounts for 1–3% of ...

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.1	100000004849	10067676	Takotsubo syndrome	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: PL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-002959-18

Sponsor Protocol Number: PRN1008-017/ACT17125

Start Date: 2023-03-23

Sponsor Name: Principia Biopharma Inc

Full Title: An open label, two-arm, Phase 2a study to evaluate the effect of rilzabrutinib (PRN1008/SAR444671) on safety and disease activity in patients with IgG4-related disease

Medical condition: IgG4-related disease

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10028395 - Musculoskeletal and connective tissue disorders	10077271	Immunoglobulin G4 related disease	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: ES (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2021-004849-20

Sponsor Protocol Number: 283PD201

Start Date: 2023-03-22

Sponsor Name: Biogen Idec Research Limited

Full Title: A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants with Parkinson’s Disease

Medical condition: Parkinson's Disease

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029205 - Nervous system disorders	10061536	Parkinson's disease	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Ongoing) ES (Ongoing) FR (Ongoing) NL (Ongoing) AT (Ongoing) PL (Ongoing) IT (Ongoing)

Trial results: (No results available)

EudraCT Number: 2023-000150-20

Sponsor Protocol Number: 1

Start Date: 2023-03-22

Sponsor Name: Bispebjerg-Frederiksberg Hospital

Full Title: The effect of exercise on pharmacodynamics and pharmacokinetics of a single dose of unfractionated heparin: A randomized, controlled, cross-over study

Medical condition: Unfractionated heparin is used for the prevention and treatment of deep vein thrombosis and complications hereof

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Adults

Gender: Male

Trial protocol: DK (Completed)

Trial results: (No results available)

Ultime prove

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici